Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study
about
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationA novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sitesExpression of SMARCF1, a truncated form of SWI1, in neuroblastomaEnergy metabolism in neuroblastoma and Wilms tumorUnveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.11q deletion in neuroblastoma: a review of biological and clinical implications.Research progress of neuroblastoma related gene variations.Paediatric urological malignancies.Neuroblastoma tumour genetics: clinical and biological aspects.Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the futureClinical significance of NTRK family gene expression in neuroblastomasMechanisms of CHD5 Inactivation in neuroblastomas.Experience with International Neuroblastoma Staging System and Pathology Classification.Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.CAMTAs: calmodulin-binding transcription activators from plants to human.The MYCN oncogene is a direct target of miR-34a.Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.Management and outcome of stage 3 neuroblastoma.Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.Genetic stratification of neuroblastoma for treatment tailoring.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Biological significance of EPHA2 expression in neuroblastoma.Homozygous deletion in a neuroblastoma cell line defined by a high-density STS map spanning human chromosome band 1p36.Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupThe International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.Knowing your ABCCs: novel functions of ABCC transporters.Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
P2860
Q24186451-D68A9AF6-2509-4DE9-A46E-6DD5B5B84F33Q24603988-FD51EFE6-9BB0-45CA-A748-450DEB2B1E1EQ24685907-1D2CE8FA-380E-44CF-BB35-7BECBA64D5DAQ26770341-01EADF95-347A-4A76-91A4-0F94F753A2D2Q31095310-3F547DB5-C4E4-4BE9-82E5-892018AC6B1BQ32174267-CC5B5C39-75E2-4816-8856-210D46176F3CQ33566987-3A0AA0EC-87DE-4D13-9F8D-89DFF07F3506Q34249635-D6976DD3-6D1D-4EE0-9D4E-DFF76449B5E6Q34453849-616AB8D4-2E1C-43CC-9500-74A1FEACBE4AQ35108252-C19138F6-4D07-4FDE-A4B6-0C8328D6F12AQ35673178-AECAAD69-5A8C-40F6-994C-A9BE20E6B82BQ35836491-AB72C212-D6B5-4002-937C-51B48E3D539CQ36623808-76E8EF69-9DA3-43DF-A253-55881F8F0711Q36649728-94A26103-F9CB-498C-8098-DBE3DC70998CQ36906282-C4BCDF55-F916-4834-AA2E-E9D62A0D9F54Q36926506-CCE49D6C-909E-4DD0-919E-AC42F1B9A441Q36944205-A9EEEAE9-6301-4491-818D-9CC0A3C8633BQ37056086-32859B93-4F68-4283-89A1-B5A36A94278CQ37085930-1FFE9A27-E4C0-4E03-8C1C-07316AAD9CCEQ37284320-3CF9A785-BB17-4643-A96F-FAC39C12A10BQ37932545-905A7B11-EC5C-433B-8776-95836075A8B4Q38014527-CC76F2A5-21C5-46F8-A1FE-90AFBF25709EQ38489272-25BB5066-6612-4A47-BFD3-329CCF7CCBEDQ38608663-58F5BDB6-99CF-44DD-9EEC-EE2353852E25Q38625880-AB2D1C34-D07E-4085-B2CE-B1A514D28A18Q39227009-F4F5DD1C-9062-4AC6-B722-23143F034788Q40795397-615153B2-CC21-4C72-8FEC-A237A3FEEBA0Q41472684-49A54937-BA16-467A-B07E-47AC663FF819Q41842569-4686810C-6264-4BCA-8E07-8B20761CA440Q41883212-5773C115-B2B5-4EC4-85B7-D7EE215B06B8Q41959730-491CDFAF-0869-427E-AFBA-9780FE347C00Q42869009-0C5DCE78-DCD3-4E2E-898C-AC2C5FB22A19Q44098566-E465DCBB-F983-4570-A441-E78D973565A4Q46527475-00CB5583-AFA8-4219-A7C8-C151F5A86CEEQ51091340-C04302C0-0B7D-440A-8251-E7CDB6E38C90Q53269806-FC6CDB8F-CE09-4051-9CE0-0E29BB626C2BQ58698690-B17A3498-D394-4693-AA30-1061440B157A
P2860
Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study
description
article
@en
im Mai 2000 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2000
@uk
name
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@en
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@nl
type
label
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@en
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@nl
altLabel
Loss of heterozygosity at 1p36 ...... Children's Cancer Group study
@en
prefLabel
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@en
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@nl
P2093
P1476
Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study
@en
P2093
Daniel O. Stram
Erik P. Sulman
Garrett M. Brodeur
John M. Maris
John N. Lukens
Katherine K. Matthay
Matthew J. Weiss
Michael D. Hogarty
Patricia M. Thompson
P304
P356
10.1200/JCO.2000.18.9.1888
P407
P577
2000-05-09T00:00:00Z